medac | Medac est historiquement un acteur de référence dans la production de cytotoxiques injectables.

Une large gamme de thérapies de première, deuxième et troisième ligne

Medac s’engage à mettre à disposition des options de traitement pour les oncologues et leurs patients. Aujourd’hui, nous couvrons une large gamme de thérapies de première, deuxième et troisième ligne pour une variété d’indications oncologiques.

Medac contribue à rendre les traitements oncologiques accessibles à un plus grand nombre de patients. Nous nous concentrons également sur des initiatives ou des partenariats avec d’autres entreprises ainsi qu’avec la communauté scientifique qui augmentent l’accessibilité de nos médicaments dans le monde.

Information for patients

Educational Material

In addition to the respective summary of product characteristics and the package leaflet, educational material approved by the national authorities is also available for some medac products. The educational material published below is the educational material approved in the respective EU Member State.

Our Focus Areas

Rheumatology

Key rheumatological treatment improved

Rheumatic diseases imply a range of chronic treatment needs across a broad spectrum of patients. With the optimisation of a key treatment in this area, medac has succeeded in bringing a significant improvement to patients' quality of life.

Urology

Addressing unmet needs with urological therapies

Urology is a focus area of highest importance for medac. We have been active in this field from almost the very beginning of our company and are focused on supplying a range of proprietary products that address a variety of unmet therapeutic needs.

Hematology

Innovative and life-saving treatment options

Hematology is a focus area of high importance for medac. To find new treatment approaches for rare diseases, medac addresses critical needs in hematology and has developed innovative products for therapies before and after stem cell transplantation.